Lefamulin acetate Catalog No.:M19291-C In a CysLT2 receptor reporter

In a CysLT2 receptor reporter cell line

28)29/h4-9

BCL6-IN-8c (Compound 8c) also exhibits good cellular PPI inhibitory activity in the submicromolar range (M2H IC50 = 0

3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone

Samuelsen JT

Lefamulin acetate Catalog No.:M19291-C In a CysLT2 receptor reporterLefamulin acetate (BC 3781 acetate) is an orally active antibiotic for community acquired bacterial pneumonia (CABP) treatment. Lefamulin acetate (BC 3781 acetate) is the first semi synthetic pleuromutilin for systemic treatment of bacterial infections in humans. Lefamulin acetate (BC 3781 acetate) inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, preventing the binding of transfer RNA for peptide